Actuate Therapeutics, Inc.
News
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
Globe Newswire Elraglusib is a Class-Leading GSK-3 Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer TrialsOrphan Drug Designation in Soft Tissue Sarcomas Expands Company's...\n more…
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
Globe Newswire Elraglusib Demonstrated Anti-Tumor Activity with Two Ongoing Durable Complete Responses and ~62% Disease Control Rate in First 8 Patients with Relapsed/Refractory Ewing and Ewing-related...\n more…
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Globe Newswire CHICAGO and FORT WORTH, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) ( Actuate or the Company ), a clinical-stage biopharmaceutical company, focused on...\n more…
Todd S. Thomson Sells 18,750 Shares of Actuate Therapeutics (NASDAQ:ACTU) Stock
Ticker Report Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) insider Todd S. Thomson sold 18,750 shares of the firm's stock in a transaction on Wednesday, August 14th. The shares were sold at an average...\n more…
